Sandra Levy
ARTICLES BY THIS AUTHOR
- 8/5/2020
Cardinal Health sees earnings dip in Q4, full year amid strong sales
For the fiscal year, Cardinal Health's operating loss was $4.1 billion. For fiscal 2020, diluted loss per share was $12.61. Fourth-quarter earnings per share were $2.23. - 8/5/2020
NACDS’ Anderson talks COVID-19, leadership and social justice at George Washington Presidential Library
NACDS president and CEO Steve Anderson participated in a wide-ranging interview with Peter Cressy, director of the George Washington Leadership Institute of the George Washington Presidential Library at Mount Vernon. - 8/5/2020
These pharmacies topped J.D. Power's 2020 survey
The J.D. Power 2020 U.S. Pharmacy Study found that nearly half (48%) of retail pharmacy customers have used at least one health- and wellness-oriented service provided by their pharmacy this year. - 8/4/2020
Camber intros mesalamine suppositories
Camber's generic Canasa suppositories treat mild to moderate ulcerative colitis. - 8/4/2020
CVS Health delivers solid Q2 against pandemic headwinds
CVS Health's Q2 revenue hit $65.3 billion, while its net income rose 54.6% to $3 billion, even as retail traffic and script fills were soft. - 8/4/2020
Bartell Drugs' 18th annual School Tools donation drive adapts to pandemic needs
Bartell Drugs, in partnership with local radio station STAR 101.5 and World Vision, has adapted the School Tools program to reflect the changing needs of students and families during the pandemic. - 8/4/2020
Endo names Christie Smith to board of directors
Christie Smith will be the seventh independent director on Endo’s nine-member board. - 8/4/2020
FDA OKs new indication for Greenwich Biosciences' Epidiolex
Epidiolex is the only FDA-approved drug that contains a purified drug substance derived from cannabis. - 8/3/2020
Aurobindo obtains FDA nod for 2 generics
Aurobindo's newly approved Gleevac and Armidex generics provide treatment options for various types of cancer. - 8/3/2020
FDA gives Lupin tentative nod for generic Jardiance
Empagliflozin tablets, 10 mg and 25 mg had a market value of roughly $4.4 billion, according to IQVIA March 2020 data.
